Concepedia

Publication | Open Access

Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

DOIFull Paper Access

213

Citations

22

References

2009

Year

Robert J. Kreitman, Maryalice Stetler‐Stevenson, Inger Margulies, Pierre Noël, David J. FitzGerald, Wyndham H. Wilson, Ira Pastan
Journal of Clinical Oncology

Abstract

BL22 activity in HCL is confirmed. Best responses to BL22 after cladribine failure are achieved before the patients develop massive splenomegaly or undergo splenectomy.

References

YearCitations

Page 1